We are a rapidly growing, Boston-based medical technology company using AI to enable clinicians to make informed decisions on cardiovascular care - leading to better patient outcomes, improved quality of care, and reduced healthcare costs. Come work at Elucid and be part of delivering on our mission to prevent heart attacks and strokes!

This role is hybrid and based out of our Boston office, open to local students.

As our software engineering intern, you’ll work closely with a dedicated mentor and experienced engineers, gaining hands-on exposure to how a growing software-as-a-medical-device (SaMD) company builds, tests, and ships production software. You’ll write and review code, build internal tools and test automation, and use Claude Code to build Claude skills that automate repeatable work for the team. It’s a great way to get an inside look at engineering in MedTech while building skills that translate directly to a future career in software development.

This is a part-time internship (with co-op options for those who want more full-time hours) starting in January 2027, with at least two in-office days a week on Monday and Wednesday. Our sunny, spacious office is located in the heart of Boston, next to Boston Common.

This is a role for someone who is a:

Curious builder who enjoys writing, testing, and debugging code, and who is eager to apply their coursework in a fast-paced, dynamic startup environment.
Strong problem-solver with solid computer science fundamentals and a sharp eye for detail.
Clear communicator who works well on a team, takes feedback gracefully, and can work independently when needed.
Resourceful, proactive learner who enjoys finding more efficient ways to get work done, including with AI tools.
Junior, senior, or co-op student pursuing a degree in Computer Science or a related field (e.g., Software Engineering, Computer Engineering, Data Science), with an interest in healthcare technology.

With these skills and experiences:

Working knowledge of at least one of Python, C++, or TypeScript.
Experience with GitHub or similar source control, including branching, committing, and opening pull requests.
Comfort using AI tools such as Claude Code or Replit for coding and problem-solving, plus curiosity about how to use them effectively and responsibly.
Previous project or internship experience (exposure to medical device, healthcare, or regulated software environments a plus).
Interest in image processing, 3D medical imaging, and supporting machine learning teams with data (prior experience is a plus but not required)

Salary: $35-$40/hour for up to an estimated 20 hours a week

----------------------------------------------------

At Elucid, we believe the best work happens in a flexible hybrid environment. Boston-area employees are encouraged to work from the office on Mondays and Wednesdays, with the option to come in additional days if they prefer. Fully remote employees outside the Boston area come in as needed.

We are an equal opportunity employer and value diversity at Elucid. We do not discriminate based on race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability.

We understand that self-doubt can sometimes prevent great candidates from applying. If you believe you can make an impact at Elucid, even if you don’t meet every qualification, we encourage you to apply!

About the company

Elucid Bioimaging provides an AI-powered SaaS platform that helps clinicians assess cardiovascular disease. Its PlaqueIQ tool non-invasively analyzes coronary CT angiography to create a 3D model of arteries and quantify plaque, including high-risk features like lipid-rich necrotic cores, with the AI trained on paired imaging and histology data. The product is regulated, with FDA clearance and CE marking, and it distinguishes itself by grounding its analysis in histology-based references rather than simple image features. The company aims to expand commercialization in North America and Europe to support precision cardiology, preventive treatment, and reduced cardiovascular events.

Company Size

51-200

Company Stage

Series D

Total Funding

$183.3M

Headquarters

Boston, Massachusetts

Founded

2013

Get referred to Elucid

See people who can refer or advise you

Simplify's Take

What believers are saying

September 2, 2026 Series D raised $55 million, lifting total funding to $185 million.
Mark Miller joined September 29, 2026 as CRO before BioIntegrated FFR-CT launch.
AI-PREDICT enrolled patients July 9, 2026, expanding clinical evidence for lesion-centric risk.

What critics are saying

BioIntegrated FFR-CT still sits under FDA 510(k) review, blocking revenue until clearance.
Heartflow already owns entrenched FFRCT reimbursement, guidelines, and commercial relationships.
One failed pivotal study or adverse FDA decision would strand Elucid as a plaque niche vendor.

What makes Elucid unique

Plaque-IQ is validated against ground-truth histology, not visual proxy scoring.
Elucid combines Plaque-IQ, BioIntegrated FFR-CT, and lesion-level reporting in one workflow.
CPT 75577 and 2026 CMS payment accelerate adoption in imaging centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options
Hybrid Work Options
Flexible Work Hours

Growth & Insights and Company News

6 month growth

-2%

1 year growth

2 year growth

Yahoo Finance

Oct 21st, 2026

Elucid wins FDA clearance for FFR-IQ, with 92.2% sensitivity in noninvasive heart scans

Elucid, a Boston-based maker of AI-powered cardiovascular imaging software, has won US Food and Drug Administration (FDA) 510(k) clearance for FFR-IQ. The software estimates fractional flow reserve (FFR) from coronary CT angiography without invasive tests. FFR-IQ uses coronary anatomy and plaque composition in its estimate. Elucid says this can help physicians identify which patients need invasive evaluation and avoid most unnecessary catheterisations. The ELUCIDATE FFR-CT study, which supported the clearance, showed sensitivity of 92.2% and specificity of 93.1%. Elucid says these are the highest of any FFR-CT validation study. The company will present the results at the Transcatheter Cardiovascular Therapeutics conference in San Diego on November 1.

Yahoo Finance

Sep 29th, 2026

Elucid hires Mark Miller as CRO ahead of BioIntegrated FFR-CT launch

Elucid, a Boston-based medical technology company developing AI-powered cardiovascular diagnostics software, has appointed Mark Miller as chief revenue officer. Miller will lead the company's commercial expansion ahead of the anticipated FDA clearance of its BioIntegrated FFR-CT software. Miller brings over 25 years of experience in cardiovascular imaging and diagnostics sales. He previously spent a decade at GE Healthcare and Philips, and served as vice president of sales at Cassling, where he led a commercial team of more than 40 professionals. Elucid's platform includes its FDA-cleared Plaque-IQ software and the pending BioIntegrated FFR-CT solution, which helps physicians identify coronary blockages non-invasively. The company focuses on advancing precision diagnosis of cardiovascular disease through AI-enabled image analysis.

Morningstar

Sep 2nd, 2026

Elucid raises $55M in Series D to commercialise AI-powered cardiovascular imaging platform

Elucid, a Boston-based medical technology company, has raised $55 million in an oversubscribed Series D financing round, bringing its total funding to approximately $185 million. The round includes participation from a large medtech company, joining as Elucid's fourth publicly traded strategic investor, alongside IAG Capital Partners and Elevage Medical Technologies. The funding will accelerate commercialisation of Elucid's AI-powered cardiovascular imaging platform. The company is preparing for full commercial launch of its BioIntegrated FFR-CT product, currently under FDA review, alongside its FDA-cleared Plaque-IQ software. Elucid's technology converts routine CT angiography into detailed insights based on plaque biology, vessel anatomy, and physiology, helping clinicians stratify at-risk patients and personalise treatment strategies for atherosclerotic cardiovascular disease.

Associated Press

Apr 15th, 2026

Elucid launches lesion inspection tool for coronary and carotid plaque analysis

Elucid has launched a new Lesion Inspection Tool for its Plaque-IQ software suite, enabling physicians to analyse coronary and carotid plaque composition at the lesion level. The tool provides detailed quantification of plaque types, including high-risk features like lipid-rich necrotic core, supporting more precise clinical decision-making. The Boston-based AI medical technology company's Plaque-IQ is the only plaque analysis technology validated against histology, the gold standard for plaque characterisation. Powered by CT-Virtual Histology, it noninvasively quantifies and classifies coronary and carotid plaque using CTA scans. The tool allows physicians to interrogate any lesion or region and access quantitative results for specific segments, helping identify features associated with heart attack and stroke risk.

HIT Consultant

Jul 22nd, 2024

Elucid Appoints Dr. Kelly Huang As Ceo

Elucid Appoints Dr. Kelly Huang as CEO. by Executive Hires 07/22/2024 Leave a Comment. Dr. Kelly Huang, CEO at ElucidWhat You Should Know: – Elucid, a company pioneering AI-powered medical technology for cardiovascular disease (CVD), has named Dr. Kelly Huang, PhD as its new President and Chief Executive Officer (CEO)

Elucid

Software Engineer Intern

About the job